Sandrine Marchand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/133874/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0205221.	3.2	13
2	A physiologically based pharmacokinetic (PBPK) model exploring the blood-milk barrier in lactating species - A case study with oxytetracycline administered to dairy cows and goats. Food and Chemical Toxicology, 2022, 161, 112848.	3.6	8
3	PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo. Frontiers in Pharmacology, 2022, 13, 842921.	3.5	0
4	Draft Genome Sequence of Kazachstania bovina Yeast Isolated from Human Infection. Mycopathologia, 2022, 187, 413-415.	3.1	4
5	Clinical Pharmacokinetics of Daptomycin. Clinical Pharmacokinetics, 2021, 60, 271-281.	3.5	20
6	Corticosteroids alter alveolar macrophage control of Lichtheimia corymbifera spores in an ex vivo mouse model. Medical Mycology, 2021, 59, 694-700.	0.7	3
7	A new PKPD model to characterize the inoculum effect of Acinetobacter baumannii on polymyxin B in vitro. Antimicrobial Agents and Chemotherapy, 2021, , AAC0178921.	3.2	4
8	Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients. Journal of Cystic Fibrosis, 2020, 19, 421-426.	0.7	5
9	Comparative pharmacokinetics of the three echinocandins in ICU patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2969-2976.	3.0	7
10	Improved antibacterial efficiency of inhaled thiamphenicol dry powders: Mathematical modelling of in vitro dissolution kinetic and in vitro antibacterial efficacy. European Journal of Pharmaceutical Sciences, 2020, 152, 105435.	4.0	5
11	Sequential Time-Kill, a Simple Experimental Trick To Discriminate between Pharmacokinetics/Pharmacodynamics Models with Distinct Heterogeneous Subpopulations versus Homogenous Population with Adaptive Resistance. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
12	Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery. Pharmaceutics, 2020, 12, 557.	4.5	6
13	Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. Journal of Antimicrobial Chemotherapy, 2019, 74, 117-125.	3.0	17
14	Semimechanistic Pharmacodynamic Modeling of Aztreonamâ€Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrugâ€Resistant Gramâ€Negative Bacteria. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 815-824.	2.5	8
15	Pharmacokinetics of Polymyxins in Animals. Advances in Experimental Medicine and Biology, 2019, 1145, 89-103.	1.6	3
16	In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 143, 35-43.	4.3	10
17	Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	2
18	Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	2

#	Article	IF	CITATIONS
19	Reassessing the dosing of cefoxitin prophylaxis during major abdominal surgery: insights from microdialysis and population pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy, 2019, 74, 1975-1983.	3.0	8
20	Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	1
21	Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation. European Journal of Pharmaceutical Research, 2019, 1, 02-11.	1.0	20
22	A Wholeâ€Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 407-422.	2.5	7
23	ls augmented renal clearance the Holy Grail of antibiotic therapy failure in ventilator-acquired pneumonia?. Anaesthesia, Critical Care & Pain Medicine, 2018, 37, 5-6.	1.4	1
24	New aerosol formulation to control ciprofloxacin pulmonary concentration. Journal of Controlled Release, 2018, 271, 118-126.	9.9	21
25	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. Journal of Pharmaceutical Sciences, 2018, 107, 1178-1184.	3.3	8
26	Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients. Journal of Antimicrobial Chemotherapy, 2018, 73, 2830-2837.	3.0	13
27	Microdialysis Study of Aztreonam-Avibactam Distribution in Peritoneal Fluid and Muscle of Rats with or without Experimental Peritonitis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
28	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 6. Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
29	Clinical Pharmacokinetics and Pharmacodynamics of Colistin. Clinical Pharmacokinetics, 2017, 56, 1441-1460.	3.5	116
30	A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. Pharmaceutical Research, 2017, 34, 333-351.	3.5	59
31	Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 2607-2612.	3.0	32
32	Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. European Journal of Pharmaceutical Sciences, 2016, 93, 184-191.	4.0	26
33	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam. Antimicrobial Agents and Chemotherapy, 2016, 60, 3196-3198.	3.2	17
34	Microdialysis as a way to measure antibiotics concentration in tissues. Pharmacological Research, 2016, 111, 201-207.	7.1	34
35	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate. Antimicrobial Agents and Chemotherapy, 2016, 60, 5085-5087.	3.2	4
36	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin. Antimicrobial Agents and Chemotherapy, 2015, 59, 6646-6647.	3.2	44

SANDRINE MARCHAND

#	Article	IF	CITATIONS
37	Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys. Pharmaceutical Research, 2015, 32, 3403-3414.	3.5	18
38	Metronidazole and Hydroxymetronidazole Central Nervous System Distribution: 2. Cerebrospinal Fluid Concentration Measurements in Patients with External Ventricular Drain. Antimicrobial Agents and Chemotherapy, 2014, 58, 1024-1027.	3.2	15
39	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin. Antimicrobial Agents and Chemotherapy, 2014, 58, 3950-3956.	3.2	55
40	Metronidazole and Hydroxymetronidazole Central Nervous System Distribution: 1. Microdialysis Assessment of Brain Extracellular Fluid Concentrations in Patients with Acute Brain Injury. Antimicrobial Agents and Chemotherapy, 2014, 58, 1019-1023.	3.2	25
41	Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 7331-7339.	3.2	148
42	Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: In vitro vs. in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 133-144.	4.3	91
43	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 1. Ciprofloxacin, Moxifloxacin, and Grepafloxacin. Antimicrobial Agents and Chemotherapy, 2014, 58, 3942-3949.	3.2	33
44	Effect of experimentally induced hypovolemia on ertapenem tissue distribution using microdialysis in rats. European Journal of Pharmaceutical Sciences, 2014, 51, 45-50.	4.0	5
45	Microdialysis in Antibiotic Research. AAPS Advances in the Pharmaceutical Sciences Series, 2013, , 103-126.	0.6	1
46	How to solve the problem of spontaneous bacterial clearance when testing new antibiotic treatment: results on experimental pneumonia due to a derepressed cephalosporinaseâ€producing <i>Enterobacter cloacae</i> . Fundamental and Clinical Pharmacology, 2013, 27, 239-243.	1.9	1
47	Microdialysis Study of Cefotaxime Cerebral Distribution in Patients with Acute Brain Injury. Antimicrobial Agents and Chemotherapy, 2013, 57, 2738-2742.	3.2	21
48	Pharmacokinetics of Daptomycin in a Patient with Severe Renal Failure Not Receiving Dialysis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2898-2899.	3.2	4
49	Modeling Approach To Characterize Intraocular Doripenem Pharmacokinetics after Intravenous Administration to Rabbits, with Tentative Extrapolation to Humans. Antimicrobial Agents and Chemotherapy, 2012, 56, 3531-3534.	3.2	1
50	Colistin Distribution in the Peritoneal Fluid of a Patient with Severe Peritonitis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4035-4036.	3.2	5
51	Aerosol Therapy with Colistin Methanesulfonate: a Biopharmaceutical Issue Illustrated in Rats. Antimicrobial Agents and Chemotherapy, 2010, 54, 3702-3707.	3.2	587
52	Removal of colistin during intermittent haemodialysis in two critically ill patients. Journal of Antimicrobial Chemotherapy, 2010, 65, 1836-1837.	3.0	48
53	Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients. Antimicrobial Agents and Chemotherapy, 2010, 54, 924-926.	3.2	40
54	Assay of Colistin and Colistin Methanesulfonate in Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. Antimicrobial Agents and Chemotherapy, 2010, 54, 1941-1948.	3.2	130

SANDRINE MARCHAND

#	Article	IF	CITATIONS
55	Nefopam Pharmacokinetics in Patients with End-Stage Renal Disease. Anesthesia and Analgesia, 2010, 111, 1146-1153.	2.2	14
56	Kinetics of Imipenem Distribution into the Peritoneal Fluid of Patients with Severe Peritonitis Studied by Microdialysis. Clinical Pharmacokinetics, 2010, 49, 323-334.	3.5	24
57	Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. Journal of Antimicrobial Chemotherapy, 2010, 65, 1753-1758.	3.0	41
58	Brain Microdialysis Study of Meropenem in Two Patients with Acute Brain Injury. Antimicrobial Agents and Chemotherapy, 2010, 54, 3502-3504.	3.2	27
59	A simple and sensitive liquid chromatography–tandem mass spectrometry assay for the quantification of ertapenem in microdialysate. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 242-245.	2.3	19
60	Application of Basic Pharmacokinetic Concepts toÂAnalysis of Microdialysis Data. Clinical Pharmacokinetics, 2008, 47, 181-189.	3.5	27
61	Microdialysis Study of Imipenem Distribution in the Peritoneal Fluid of Rats with Experimental Acute Pancreatitis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1516-1518.	3.2	6
62	Lung Microdialysis Study of Levofloxacin in Rats following Intravenous Infusion at Steady State. Antimicrobial Agents and Chemotherapy, 2008, 52, 3074-3077.	3.2	14
63	Diffusion péritonéale des antibiotiques. , 2007, , 41-50.		0
64	Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12†mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Medicine, 2006, 32, 775-779.	8.2	600
65	Microdialysis Study of Imipenem Distribution in the Intraperitoneal Fluid of Rats with or without Experimental Peritonitis. Antimicrobial Agents and Chemotherapy, 2006, 50, 34-37.	3.2	12
66	Norfloxacin Blood-Brain Barrier Transport in Rats Is Not Affected by Probenecid Coadministration. Antimicrobial Agents and Chemotherapy, 2006, 50, 371-373.	3.2	6
67	Microdialysis Study of Imipenem Distribution in Skeletal Muscle and Lung Extracellular Fluids of Acinetobacter baumannii -Infected Rats. Antimicrobial Agents and Chemotherapy, 2006, 50, 2265-2267.	3.2	19
68	Lack of Effect of Experimental Hypovolemia on Imipenem Muscle Distribution in Rats Assessed by Microdialysis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4974-4979.	3.2	10
69	Pharmacokinetic Modeling of Free Amoxicillin Concentrations in Rat Muscle Extracellular Fluids Determined by Microdialysis. Antimicrobial Agents and Chemotherapy, 2005, 49, 3702-3706.	3.2	17
70	Microdialysis Study of Imipenem Distribution in Skeletal Muscle and Lung Extracellular Fluids of Noninfected Rats. Antimicrobial Agents and Chemotherapy, 2005, 49, 2356-2361.	3.2	36
71	Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. British Journal of Pharmacology, 2004, 142, 323-330.	5.4	21
72	Extension of the Isobolographic Approach to Interactions Studies Between More than Two Drugs: Illustration with the Convulsant Interaction between Pefloxacin, Norfloxacin, and Theophylline in Rats. Journal of Pharmaceutical Sciences, 2004, 93, 553-562.	3.3	1

#	Article	IF	CITATIONS
73	Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. Journal of Pharmaceutical Sciences, 2003, 92, 2458-2465.	3.3	15
74	Norfloxacin-Induced Electroencephalogram Alteration and Seizures in Rats Are Not Triggered by Enhanced Levels of Intracerebral Glutamate. Antimicrobial Agents and Chemotherapy, 2003, 47, 3660-3662.	3.2	5
75	Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. Pharmaceutical Research, 2002, 19, 209-214.	3.5	34
76	Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. British Journal of Pharmacology, 2000, 129, 1609-1616.	5.4	8
77	In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. European Journal of Pharmaceutical Sciences, 2000, 12, 85-93.	4.0	85